Compare Innovative Industrial Properties Inc (IIPR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Novo Nordisk A/S — how do they compare? Innovative Industrial Properties Inc trades at $51.94 (market cap $1.43B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 115.6× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (14.64%). Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and Novo Nordisk A/S for 116 Days on average.
| IIPR | NVO | |
|---|---|---|
Market Cap | $1.43B | $165.31B |
Volume | 394,222 | 11,432,838 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $63.98 |
52-Week Low | $44.58 | $35.29 |
Typical Hold Time | 86 Days | 116 Days |
Enterprise Value | $1.96B | $179.56B |
Dividend Yield | 14.64% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.83, up 1.17% on the day, with a bearish technical signal and mixed earnings history. The stock shows attractive valuation ratios, including a P/E of 11.75 and P/B of 0.83, but revenue declined to $265.96M in 2025. Recent news highlights a $245 million mezzanine loan commitment and a quarterly dividend of $1.90, underscoring its REIT structure and focus on cannabis real estate.
The outlook is cautious due to tenant defaults and dividend sustainability concerns, though the stock offers a high yield and potential regulatory catalysts. Risks include sector volatility and financial performance pressures, while analyst consensus leans hold with a $84.67 price target suggesting upside if operational stability improves.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
